Get the Stockscreener App
508.75
2.06%
10.25
After Hours:
508.75
Vertex Pharmaceuticals Inc stock is traded at $508.75, with a volume of 2.24M.
It is up +2.06% in the last 24 hours and down -1.14% over the past month.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
See More
Previous Close:
$498.50
Open:
$514.91
24h Volume:
2.24M
Relative Volume:
1.74
Market Cap:
$128.95B
Revenue:
$12.34B
Net Income/Loss:
$4.34B
P/E Ratio:
30.16
EPS:
16.8685
Net Cash Flow:
$3.71B
1W Performance:
+1.09%
1M Performance:
-1.14%
6M Performance:
+15.18%
1Y Performance:
+24.72%
1-Day Range:
$507.21
$517.68
1-Week Range:
$484.08
$517.68
52-Week Range:
$403.16
$560.25
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
Name
Vertex Pharmaceuticals Inc
Sector
Industry
Phone
(617) 341-6393
Address
50 NORTHERN AVENUE, BOSTON, MA
Compare VRTX vs MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
508.75 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.34 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.27 | 53.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.08 | 42.32B | 5.76B | 514.49M | 1.10B | 4.4813 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-21-26 | Initiated | Leerink Partners | Outperform |
| Sep-02-26 | Resumed | Morgan Stanley | Overweight |
| May-27-26 | Resumed | Truist | Buy |
| Mar-18-26 | Upgrade | Maxim Group | Hold → Buy |
| Mar-10-26 | Initiated | Jefferies | Buy |
| Mar-10-26 | Reiterated | Oppenheimer | Outperform |
| Feb-13-26 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-28-26 | Resumed | Barclays | Overweight |
| Jan-22-26 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jan-12-26 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Jan-07-26 | Resumed | UBS | Buy |
| Jan-06-26 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Dec-03-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Sep-25-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Sep-03-25 | Initiated | Raymond James | Mkt Perform |
| Aug-06-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| May-07-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| May-06-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Overweight |
| Feb-12-25 | Upgrade | Canaccord Genuity | Sell → Hold |
| Feb-11-25 | Upgrade | Canaccord Genuity | Sell → Hold |
| Jan-30-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-20-24 | Reiterated | H.C. Wainwright | Buy |
| Dec-19-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-09-24 | Upgrade | Jefferies | Hold → Buy |
| Nov-14-24 | Initiated | Citigroup | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Perform |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Aug-05-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Jun-27-24 | Initiated | Redburn Atlantic | Buy |
| Apr-11-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Feb-06-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-02-24 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-31-24 | Downgrade | Maxim Group | Buy → Hold |
| Jan-31-24 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-24-24 | Downgrade | Canaccord Genuity | Hold → Sell |
| Dec-14-23 | Reiterated | RBC Capital Mkts | Sector Perform |
| May-30-23 | Initiated | William Blair | Outperform |
| May-04-23 | Resumed | Piper Sandler | Overweight |
| Mar-21-23 | Initiated | Bernstein | Outperform |
| Jan-18-23 | Initiated | Canaccord Genuity | Hold |
| Jan-17-23 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Dec-19-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-01-22 | Upgrade | Maxim Group | Hold → Buy |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| May-06-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-03-22 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-03-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jan-27-22 | Reiterated | JP Morgan | Overweight |
| Jan-27-22 | Reiterated | Morgan Stanley | Underweight |
| Jan-27-22 | Reiterated | RBC Capital Mkts | Outperform |
| Jan-27-22 | Reiterated | Stifel | Hold |
| Jan-27-22 | Reiterated | Wolfe Research | Outperform |
| Jan-20-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Nov-19-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Sep-09-21 | Downgrade | Stifel | Buy → Hold |
| Sep-07-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jul-20-21 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-19-21 | Resumed | Wolfe Research | Outperform |
| Jul-01-21 | Initiated | Raymond James | Mkt Perform |
| Jun-11-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Feb-23-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Feb-02-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-30-20 | Initiated | Daiwa Securities | Outperform |
| Nov-30-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-20-20 | Initiated | Bernstein | Outperform |
| Oct-28-20 | Initiated | UBS | Buy |
| Jul-31-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-30-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-28-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-31-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Nov-19-19 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| Sep-03-19 | Upgrade | Goldman | Neutral → Buy |
| Aug-01-19 | Downgrade | Needham | Buy → Hold |
| May-23-19 | Resumed | Citigroup | Buy |
| May-21-19 | Initiated | Credit Suisse | Outperform |
| Apr-12-19 | Initiated | Evercore ISI | In-line |
| Mar-26-19 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-19-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Feb-06-19 | Downgrade | Maxim Group | Buy → Hold |
View All
Vertex Pharmaceuticals Inc Stock (VRTX) Latest News
Moderna vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Which iShares Healthcare ETF Is the Better Buy: Biotech-Focused IBB or Broad IYH? - The Motley Fool
Vertex Pharmaceuticals (VRTX) Beats Stock Market Upswing: What Investors Need to Know - Zacks Investment Research
Is Vertex Stock Worth More Than Its Competitors? - Trefis
If You Invested $100 In Vertex Pharmaceuticals Stock 5 Years Ago, You Would Have This Much Today - Benzinga
RBC raises target for Vertex Pharma stock from USD 570 to USD 576 - AD HOC NEWS
RBC Lifts Price Target on Vertex Pharmaceuticals to $576 From $570, Keeps Outperform Rating - www.marketscreener.com
Vertex to Announce Third Quarter 2026 Financial Results November 2nd - Business Wire
Vertex Pharmaceuticals Incorpor (VRTX) Stock forecasts - Yahoo Finance UK
Vertex Pharma stock after-hours at EUR 446.63: minus 0.62 percent versus prior close - AD HOC NEWS
Vertex Pharmaceuticals Incorpor (VRTX) Stock Forecasts - Yahoo Finance
Novavax (NVAX) Surges 20.1%: Is This an Indication of Further Gains? - Zacks Investment Research
Healthcare Sector Highlights 16 A+ Growth Stocks Including Verte - GuruFocus
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Amgen vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026? - The Motley Fool
Vertex (VRTX) or Regeneron (REGN)? Two Biotech Moats, Two Very Different Bets - Yahoo Finance
Vertex Pharmaceuticals And 2 Other Top Gene Therapy Stocks - Yahoo Finance
Vertex Pharmaceuticals (VRTX) Stock Falls Amid Market Uptick: What Investors Need to Know - Zacks Investment Research
Vertex Pharmaceuticals (VRTX) Stock Falls Amid Market Uptick: What Investors Need to Know - Yahoo Finance
Vertex Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Vertex Pharmaceuticals Inc Stock (VRTX) Moved Down by 3.21% on Oct 1: What Investors Need To Know - TradingKey
M&A slows in Q3 but Vertex snags one of the year’s biggest in $10B Crinetics buy - BioSpace
$100 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth This Much Today - Benzinga
Vertex Pharmaceuticals- Still Too Much Emphasis On CF SupremacyI Foresee A Downgrade - Seeking Alpha
2 Wall Street Analysts Think Vertex Pharmaceuticals Stock Can Soar Another 20% or More Over the Next 12 Months. Here's Why They're Right. - The Motley Fool
UBS Raises Vertex Pharmaceuticals Price Target to $615 From $585, Maintains Buy Rating - Moomoo
2 Wall Street Analysts Think Vertex Pharmaceuticals Stock Can Soar Another 20% or More Over the Next 12 Months. Here's Why They're Right. - Yahoo Finance
Could Vertex Pharmaceuticals (VRTX)’s Kidney Breakthrough Unlock a New Opportunity for Maze Therapeutics (MAZE)? - Yahoo Finance
Vertex Pharmaceuticals Incorpor (VRTX) Stock Forecasts - Yahoo Finance
Vertex Pharmaceuticals Incorporated (VRTX) Options ChainYahoo Finance - Yahoo! Finance Canada
Vertex Pharmaceuticals (VRTX) Increases Despite Market Slip: Here's What You Need to Know - Yahoo Finance
Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
BMO Capital Remains a Buy on Vertex Pharmaceuticals (VRTX) - The Globe and Mail
Vertex Pharmaceuticals (VRTX) Gets a Hold from Canaccord Genuity - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX) and Roivant Sciences (ROIV) - The Globe and Mail
Vertex (VRTX) Stock Could Be 24% Undervalued As Kidney Trial Progress Continues - Yahoo Finance
Vertex Pharma options analysis: heavy put activity signals near-term caution - Investing.com
Vertex Posts Positive Phase II Data on Kidney Disease Drug - Zacks Investment Research
Vertex Pharmaceuticals Incorporated (VRTX) Options ChainYahoo Finance - Yahoo! Finance Canada
Vertex Pharmaceuticals (VRTX) Q2 2026 Earnings Call Transcript - fortune.com
Better Healthcare ETF: Invesco's Biotech-Focused IBBQ vs. iShares' Broad IYH - The Motley Fool
The Surprise That Sent Vertex — And Its Chief Rival — Soaring - Investor's Business Daily
Vertex Pharmaceuticals Stock Gains On Kidney Drug DataVertex Pharmaceuticals (NASDAQ:VRTX) - Benzinga
Twin Moves: VRTX Rises On Kidney Disease Trial Results, MAZE Rallies Harder - Yahoo Finance
Vertex’s Kidney Drug Success Sparks a 22% Surge for This Rival Biotech - Barron's
Vertex Pharmaceuticals stock gains as inaxaplin data advance - AD HOC NEWS
Vertex Announces Positive Results From Phase 2b AMPLIFIED Study of Inaxaplin in Additional Populations of People With APOL1-Mediated Kidney Disease (AMKD) and Completion of Enrollment in the Phase 2/3 AMPLITUDE Trial - BioSpace
Vertex’s midstage data amplify kidney disease market opportunity - Fierce Biotech
Vertex Pharmaceuticals Reports Positive Results for Inaxaplin Kidney Disease Trial - marketscreener.com
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Vertex Pharmaceuticals Inc Stock (VRTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Vertex Pharmaceuticals Inc Stock (VRTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Tatsis Ourania | EVP, Chief Reg. & Quality Off. |
Jul 02 '26 |
Sale |
524.99 |
1,500 |
787,485 |
45,321 |
| McKechnie Duncan | EVP, Chief Commercial Officer |
Jul 02 '26 |
Sale |
519.00 |
1,541 |
799,779 |
11,001 |
| Tatsis Ourania | Officer |
Jul 02 '26 |
Proposed Sale |
524.99 |
1,500 |
787,485 |
0 |
| McKechnie Duncan | Officer |
Jul 02 '26 |
Proposed Sale |
519.00 |
1,541 |
799,779 |
0 |
| Liu Joy | EVP and Chief Legal Officer |
Jul 01 '26 |
Sale |
502.71 |
828 |
416,244 |
19,131 |
| Liu Joy | Officer |
Jul 01 '26 |
Proposed Sale |
502.71 |
828 |
416,244 |
0 |
| Bozic Carmen | EVP and CMO |
Jun 26 '26 |
Sale |
482.50 |
596 |
287,570 |
15,337 |
| Bozic Carmen | Officer |
Jun 26 '26 |
Proposed Sale |
482.50 |
596 |
287,570 |
0 |
| Bozic Carmen | Officer |
Jun 18 '26 |
Proposed Sale |
462.17 |
1,020 |
471,413 |
0 |
| Bozic Carmen | EVP and CMO |
Jun 18 '26 |
Sale |
462.17 |
1,020 |
471,413 |
15,933 |
4.51%
2.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):